Tangeritin is one of the Citrus bioflavonoids. Tangeritin may play a role, like many flavonoids, in reducing the risk for certain cancers. Tangeritin has also shown promise in protecting nerve cells.

Sytrinol has polymethoxylated flavones (PMFs) that decrease apoprotein B, a structural protein needed for endogenous synthesis of LKL cholesterol. PMFs (tangeritin and nobiletin) decrease diacylglycerol acetyl transferase, a liver enzyme needed for endogenous synthesis of triblycerides. Sytrinol has been promoted for those with cholesterol issues. You can find Sytrinol here.

Tangeritin and cancer
Treatment of metastatic melanoma B16F10 by the flavonoids tangerotin, rutin, and diosmin.
J Agric Food Chem. 2005 Aug 24;53(17):6791-7. Pathology Department, Faculty of Medicine, University of Murcia, 30100 Espinardo, Murcia, Spain.
Melanoma is one of the most frequently metastasizing malignant neoplasias. This study examines an experimental model of pulmonary metastasis and the B16F10 cell subline, highly metastatic in the lung. Antimetastatic effects of the flavonoids tangeritin, rutin, and diosmin were analyzed, and at the same time an analysis of the metastatic activity of ethanol was performed, considered to be necessary because it is used as a vehicle for administering the flavonoids. The greatest reduction in the number of metastatic nodules (52%) was obtained with diosmin. Rutin- and tangeritin treated groups also showed reductions of the same index compared with the ethanol group. It would seem that structural factors would better explain these results and the antimetastatic activity of each flavonoid and the respective metabolites.

Tangeritin Research Update
A safety study of oral tangeretin and xanthohumol administration to laboratory mice.
In Vivo. 2005 Jan-Feb;19(1):103-7.
The detection of molecular targets for flavonoids in cell signalling has opened new perspectives for their application in medicine. Both tangeretin, a citrus methoxyflavone, and xanthohumol, the main prenylated chalcone present in hops (Humulus lupulus L.), act on the mitogen-activated protein kinase pathway and await further investigation for administration in vivo. A safety study was designed in laboratory mice orally administered concentrates of purified tangeretin (1 x 10(-4) M) or xanthohumol (5 x 10(-4) M) at libitum for 4 weeks. Blood samples were collected for the analysis of a variety of haematological and biochemical parameters. A reduction of the circulating lymphocyte number was noticed for tangeretin, while all other parameters were unaffected by treatment with either tangeretin or xanthohumol. The parameters encompassed an integrity check of the following tissues and organs: bone marrow, liver, exocrine pancreas, kidneys, muscles, thyroid, ovaries and surrenal cortex. Furthermore, no differences were noted in the metabolism of proteins, lipids, carbohydrates and uric acid, as well as in ion concentrations. CONCLUSION: All data indicate that oral administration of tangeretin or xanthohumol to laboratory mice does not affect major organ functions and opens the gate for further safety studies in humans.

Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation.
FEBS Lett. 2005 Mar 14;579(7):1665-9.
Tangeretin is a methoxyflavone from citrus fruits, which inhibits growth of human mammary cancer cells and cytolysis by natural killer cells. Attempting to unravel the flavonoid's action mechanism, we found that it inhibited extracellular-signal-regulated kinases 1/2 (ERK1/2) phosphorylation in a dose- and time-dependent way. In human T47D mammary cancer cells this inhibition was optimally observed after priming with estradiol. The spectrum of the intracellular signalling kinase inhibition was narrow and comparison of structural congeners showed that inhibition of ERK phosphorylation was not unique for tangeretin. Our data add tangeretin to the list of small kinase inhibitors with a restricted intracellular inhibition profile.

Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease.
Neuroreport. 2001 Dec 4;12(17):3871-5.
Neuroprotective effects of a natural antioxidant tangeritin, a citrus flavonoid, were elucidated in the 6-hydroxydopamine (6-OHDA) lesion rat model of Parkinson's disease (PD), after bioavailability studies. Following the chronic oral administration (10 mg/kg/day for 28 days), significant levels of tangeritin were detected in the hypothalamus, striatum and hippocampus. These studies, for the first time, give evidence that tangeritin crosses the blood-brain barrier. The significant protection of striato-nigral integrity and functionality by tangeritin suggests its potential use as a neuroprotective agent.

Additional links
Tongkatali.net research
Tribulusterrestrisextract.com research
Yohimbebark.net research